Literature DB >> 3096197

Norfloxacin in the therapy of uncomplicated gonorrhea.

B Romanowski, H Wood, J Draker, M C Tsianco.   

Abstract

In an open study, 70 patients with uncomplicated anogenital Neisseria gonorrhoeae infection were evaluated to determine the efficacy and safety of a single oral dose of norfloxacin (800 mg). Norfloxacin cured all 31 male urethral and 25 endocervical infections. All 63 isolates of N. gonorrhoeae tested were inhibited by 0.05 microgram of norfloxacin per ml.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3096197      PMCID： PMC180593          DOI： 10.1128/AAC.30.3.514

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Single doses of methacycline and doxycycline for gonorrhea: a cooperative study of the frequency and cause of treatment failure.

Authors:  P J Wiesner; K K Holmes; P F Sparling; M J Maness; D M Bear; L T Gutman; W W Karney
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

4.  Comparative in-vitro activity of norfloxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae.

Authors:  R L Sweet; M J Ohm-Smith; W K Hadley
Journal:  J Antimicrob Chemother       Date:  1982-12       Impact factor: 5.790

5.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.

Authors:  S R Crider; S D Colby; L K Miller; W O Harrison; S B Kerbs; S W Berg
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

8.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors:  F W Heessen; H L Muytjens
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

10.  Evaluation of the Phadebact Gonococcus Test for confirmation of Neisseria gonorrhoeae.

Authors:  C M Anand; E M Kadis
Journal:  J Clin Microbiol       Date:  1980-07       Impact factor: 5.948
  10 in total
  5 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.

Authors:  Edward W Hook; Robert D Kirkcaldy
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

3.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

4.  Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group.

Authors:  M Tanaka; T Matsumoto; M Sakumoto; K Takahashi; T Saika; I Kabayashi; J Kumazawa
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.